Suven Life Sciences granted patents for neurodegenerative drug

Tags: Companies
Pharmaceutical firm Suven Life Sciences has been granted three product patents -- one each by South Korea, China and Canada -- for drug used in the treatment of neurodegenerative diseases.

Neurodegenerative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.

In a BSE filing the company said it has been granted "one product patent from South Korea, one product patent from China and one product patent from Canada corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".

These patents are valid through 2029, 2029 and 2031, respectively, the company said in a BSE filing.

Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 14 granted patents from South Korea, 14 from China and 16 from Canada, respectively.

EDITORIAL OF THE DAY

  • Scorpene leak has dented the navy’s efforts to beef up its dwindling fleet

    Defence deals in our country, which is the world’s largest importer of arms and ammunition, always have the potential to turn murky.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Urs Schoettli

Japan needs more women in high office

Japan does not rank high in international tables, when it ...

Jemima Raman

Things one learns on a potter's wheel

As things go, watching a shape emerge from a blob ...

Bubbles Sabharwal

Hold the world in the palm of your hand

There is absolute happiness and relative happiness. The poet John ...